Login / Signup

Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase Inhibitors: Expeditious Reconstruction of Suboptimal Hits into a Series with Potent in Vivo Activity.

Jennifer A BorthwickCarlos AlemparteIan WallBenjamin C WhitehurstArgyrides ArgyrouGlenn A BurleyPaco de Dios-AntonLaura GuijarroMaria Candida MonteiroFatima OrtegaColin J SucklingJulia Castro PichelMónica CachoRobert J Young
Published in: Journal of medicinal chemistry (2020)
Decaprenylphosphoryl-β-d-ribose 2'-epimerase (DprE1) is an essential enzyme in Mycobacterium tuberculosis and has recently been studied as a potential drug target, with inhibitors progressing to clinical studies. Here we describe the identification of a novel series of morpholino-pyrimidine DprE1 inhibitors. These were derived from a phenotypic high-throughput screening (HTS) hit with suboptimal physicochemical properties. Optimization strategies included scaffold-hopping, synthesis, and evaluation of fragments of the lead compounds and property-focused optimization. The resulting optimized compounds had much improved physicochemical properties and maintained enzyme and cellular potency. These molecules demonstrated potent efficacy in an in vivo tuberculosis murine infection model.
Keyphrases
  • mycobacterium tuberculosis
  • pulmonary tuberculosis
  • anti inflammatory
  • emergency department
  • adverse drug
  • drug induced
  • electronic health record